Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

 A number of energetic vaccination approaches have confirmed ineffective in lowering the substantial morbidity and mortality attributable to respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a considerable and sustainable enhance in neutralising exercise is required to guard towards extreme RSV illness. To that finish, we evaluated the security and immunogenicity of DS-Cav1, a prefusion F subunit vaccine. On this part 1 research, DS-Cav1 vaccination was secure and effectively tolerated. DS-Cav1 vaccination elicited a strong enhance in RSV F-specific antibodies and neutralising exercise that was sustained above baseline for no less than 44 weeks.

On this randomised, open-label, part 1 scientific trial, the stabilised prefusion F vaccine DS-Cav1 was evaluated for dose, security, tolerability, and immunogenicity in wholesome adults aged 18-50 years at a single US web site. Individuals had been assigned to obtain escalating doses of both 50 μg, 150 μg, or 500 μg DS-Cav1 at weeks Zero and 12, and had been randomly allotted in a 1:1 ratio inside every dose group to obtain the vaccine with or with out aluminium hydroxide (AlOH) adjuvant. A single low-dose of pre-F immunisation of antigen-experienced people may confer safety that extends all through a complete RSV season.

After 71 individuals had been randomised, the protocol was amended to permit some individuals to obtain a single vaccination at week 0. The first goals evaluated the security and tolerability at each dose inside 28 days following every injection. Neutralising exercise and RSV F-binding antibodies had been evaluated from week Zero to week 44 as secondary and exploratory goals. Security was assessed in all individuals who acquired no less than one vaccine dose; secondary and exploratory immunogenicity evaluation included all individuals with out there knowledge at a given go to.

European knowledge sources for computing burden of (potential) vaccine-preventable illnesses in ageing adults

To information decision-making on immunisation programmes for ageing adults in Europe, one of many goals of the Vaccines and InfecTious illnesses within the Ageing popuLation (IMI2-VITAL) venture is to evaluate the burden of illness (BoD) of (doubtlessly) vaccine-preventable illnesses ((P)VPD). We aimed to establish the out there knowledge sources to calculate the BoD of (P)VPD in taking part VITAL international locations and to pinpoint knowledge gaps. Primarily based on epidemiological standards and vaccine availability, we prioritized (P) VPD attributable to Further-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.

Morbidity and mortality knowledge had been typically out there for all 5 illnesses, whereas abstract BoD estimates had been largely missing. Out there knowledge weren’t all the time stratified by age and danger group, which is very necessary when calculating BoD for ageing adults. AMR knowledge had been out there in a number of international locations for S. aureus and ExPEC. This research offers an exhaustive overview of the out there knowledge sources and knowledge gaps for the estimation of BoD of 5 (P) VPD in ageing adults within the EU/EAA, which is helpful to information pathogen-specific BoD research and contribute to calculation of (P)VPDs BoD.

Respiratory syncytial virus (RSV) is a typical pathogen inflicting extreme respiratory sickness in infants and elder adults. The event of an efficient RSV vaccine is a crucial unmet medical want and an space of energetic analysis. The normal methodology for testing neutralizing antibodies towards RSV in scientific trials is the plaque discount neutralization take a look at (PRNT), which makes use of 24-well plates and wishes six days publish an infection to develop viral plaques.

On this research, we’ve got developed a virus discount neutralization take a look at (VRNT), which permits the variety of RSV contaminated cells to be routinely counted by an imaging cytometer at someday publish an infection in 96-well plates. VRNT was discovered sturdy to cell seeding density, detection antibody focus, virus enter and an infection time.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Balancing Precision vs. Cohort Transcriptomic Evaluation of Acute and Restoration Part of Viral Bronchiolitis

Viral infections affecting the decrease respiratory tract place monumental burdens on hospitals. As neither vaccines nor anti-viral brokers exist for a lot of viruses, understanding danger elements and outcomes in every affected person utilizing minimally invasive evaluation, similar to blood, can result in improved healthcare supply. A cohort of PAXGene RNAseq of infants admitted with reasonable or extreme acute bronchiolitis and respiratory syncytial virus (RSV) had been in contrast with case-control statistical evaluation and cohort-based outlier mapping for precision transcriptomics.

Extreme bronchiolitis sufferers had signatures linked to the immune system, interferon signaling, and cytokine signaling, with marked intercourse variations in XIST, RPS4Y1, KDM5D, and LINC00278 for severity. A number of sufferers had distinctive secondary infections, cytokine activation, immune responses, organic pathways, and immune cell activation, highlighting the necessity for outlining patient-level transcriptomic signatures. Balancing relative contributions of cohort-based biomarker discoveries with affected person’s organic responses is required to grasp totality of mechanisms of hostile outcomes in viral bronchiolitis.

Orf virus VEGF-E Recombinant Protein

300-044 5 µg
EUR 136.5
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Orf virus VEGF-E Recombinant Protein

300-044S 2 µg
EUR 73.5
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Orf virus VEGF-E Recombinant Protein

300-045 20 µg
EUR 357
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-1mg

QP10912-1mg 1mg
EUR 6181.2

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-2ug

QP10912-2ug 2ug
EUR 186

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-10ug

QP10912-10ug 10ug
EUR 241.2

Orf virus VEGF-E, Heparin-binding Recombinant Protein

300-046 20 µg
EUR 194.25
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1.

Orf virus VEGF-E, Heparin-binding Recombinant Protein

300-046S 5 µg
EUR 94.5
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1.

VEGF-E Vascular Endothelial Growth Factor-E Recombinant Protein(Orf Virus)

PROTQ2F842 Regular: 10ug
EUR 380.4
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa.

ov-VEGF-E (Orf virus) (Recombinant) Human

GWB-C8AD60 0.005 mg Ask for price

VEGFE protein (Orf virus)

30R-AV011 5 ug
EUR 381
Description: Purified recombinant VEGFE protein (Orf virus)

Recombinant Orf Virus VEGFE Protein

VAng-Lsx0417-inquire inquire Ask for price
Description: Orf Virus VEGFE, recombinant protein from Baculovirus.

Recombinant Orf Virus VEGFE Protein [His]

VAng-Lsx0418-inquire inquire Ask for price
Description: Orf Virus VEGFE [His], recombinant protein from E. coli.

Anti-Hepatitis E Virus Antibody

18606 100ug
EUR 397

Deoxybrevianamide E

D083-1MG 1 mg
EUR 187.71
Description: C21H25N3O2

Deoxybrevianamide E

D083-5MG 5 mg
EUR 656.34
Description: C21H25N3O2

Berkeleylactone E

B087-1MG 1 mg
EUR 142.63
Description: C20H32O7  

Berkeleylactone E

B087-5MG 5 mg
EUR 498.97
Description: C20H32O7  

Chevalone E

C257-0.5MG 0.5 mg
EUR 150.43
Description: C20H24O4  

Chevalone E

C257-2.5MG 2.5 mg
EUR 525.85
Description: C20H24O4  

Cytochalasin E

C197-1MG 1 mg
EUR 77.6
Description: C28H33NO7

Cytochalasin E

C197-5MG 5 mg
EUR 270.51
Description: C28H33NO7

Roquefortine E

R035-1MG 1 mg
EUR 146.96
Description: C27H31N5O2

Roquefortine E

R035-5MG 5 mg
EUR 513.71
Description: C27H31N5O2

Oligomycin E

O021-1MG 1 mg
EUR 207.65
Description: C45H72O13

Oligomycin E

O021-5MG 5 mg
EUR 726.13
Description: C45H72O13

Paraherquamide E

P070-0.5MG 0.5 mg
EUR 265.74
Description: C28H35N3O4

Paraherquamide E

P070-2.5MG 2.5 mg
EUR 928.58
Description: C28H35N3O4

Phenelfamycin E

P078-1MG 1 mg
EUR 207.65
Description: C65H95NO21

Phenelfamycin E

P078-5MG 5 mg
EUR 726.13
Description: C65H95NO21

Hepatitis E virus ORF 2 recombinant antigen

8942 100 ug
EUR 477.6
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB.

Hepatitis E virus ORF 2 recombinant antigen

8943 100 ug
EUR 477.6
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB.

Hepatitis E virus ORF 3 recombinant antigen

8944 100 ug
EUR 477.6
Description: This is Hepatitis E virus ORF 3 recombinant antigen for ELISA,WB.

Azithromycin impurity E EvoPure®

A074-5MG 5 mg
EUR 593.04
Description: C36H68N2O12

Anti-Hepatitis B Virus E Antigen Antibody

E38A9902 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody

E38A9925 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Zika Virus Envelope Protein E Antibody

STJ503579 100 µg
EUR 571.2

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (EB2)

MAB12412-100 0.1
EUR 276.84
Description: Purified monoclonal antibody against Hepatitis E virus capsid (ORF2).

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (EB2)

MAB12412-500 0.5
EUR 692.74
Description: Purified monoclonal antibody against Hepatitis E virus capsid (ORF2).

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (BD6)

MAB12413-100 0.1
EUR 276.84
Description: Purified Monoclonal Antibody

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (BD6)

MAB12413-500 0.5
EUR 692.74
Description: Purified Monoclonal Antibody

Hepatitis E Virus antibody

70R-HR003 100 ug
EUR 295
Description: Affinity purified Rabbit polyclonal Hepatitis E Virus antibody

Hepatitis E virus

Oneq-H498-OneqH498100R Oneq-H498-100R
EUR 1028

Hepatitis E virus

Oneq-H498-OneqH498150R Oneq-H498-150R
EUR 1438

Hepatitis E virus

Oneq-H498-OneqH49850R Oneq-H498-50R
EUR 728

Hepatitis E virus

PCR-H498-PCRH49848R PCR-H498-48R
EUR 485

Hepatitis E virus

PCR-H498-PCRH49896R PCR-H498-96R
EUR 685

Hepatitis E virus ORF 3 Recombinant Protein

53-335 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 3 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein

53-336 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 2 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein

53-337 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 2 Recombinant Protein

Goat anti-Hepatitis B Virus E Antigen Antibody

DL95826A-100ul 100 ul
EUR 370
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Goat anti-Hepatitis B Virus E Antigen Antibody

DL95826A-50ul 50 ul
EUR 259
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Goat anti-Hepatitis B Virus E Antigen Antibody

YLD8369-100ul 100 ul
EUR 320
Description: Goat polyclonal antibody to Hepatitis B Virus E Antigen

Goat anti-Hepatitis B Virus E Antigen Antibody

YLD8369-50ul 50 ul
EUR 200
Description: Goat polyclonal antibody to Hepatitis B Virus E Antigen

Mouse anti-Hepatitis B Virus E Antigen Antibody

DL95804A-100ul 100 ul
EUR 370
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Mouse anti-Hepatitis B Virus E Antigen Antibody

DL95804A-50ul 50 ul
EUR 259
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Mouse anti-Hepatitis B Virus E Antigen Antibody

YLD8466-100ul 100 ul
EUR 320
Description: Mouse monoclonal antibody to Hepatitis B Virus E Antigen

Mouse anti-Hepatitis B Virus E Antigen Antibody

YLD8466-50ul 50 ul
EUR 200
Description: Mouse monoclonal antibody to Hepatitis B Virus E Antigen

Hepatitis E Virus ORF3 Protein

20-abx260138
  • Ask for price
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 100 ug
  • 1 mg

Hepatitis E Virus ORF3 Protein

abx260138-20g 20 µg
EUR 950

Hepatitis E Virus ORF3 Protein

abx260138-5g 5 µg
EUR 350

Anti-Zika Virus Envelope Protein E Antibody FITC

STJ503581 100 µg
EUR 703.2

human anti-Dengue Virus E(pan-specific) IgG

E4A11A62-G 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-Dengue Virus E(pan-specific) IgM

E4A11A62-M 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Anti-Zika Virus Envelope Protein E Antibody BIOTIN

STJ503580 100 µg
EUR 703.2

Vascular Endothelial Growth Factor-E (Orf Virus) Protein

20-abx263083
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 1 mg
  • 2 µg

Vascular Endothelial Growth Factor-E (Orf Virus) Protein

abx263083-10mg 10 mg
EUR 325

Vascular Endothelial Growth Factor-E (Orf Virus) Protein

abx263083-25mg 25 mg
EUR 6500

Vascular Endothelial Growth Factor-E (Orf Virus) Protein

abx263083-5mg 5 mg
EUR 225

Hepatitis E Virus ORF3 (Recombinant)

22060181-1 100 µg
EUR 264.47

Recombinant Hepatitis E Virus ORF3 

7-07450 100µg Ask for price

Recombinant Hepatitis E Virus ORF3 

7-07451 500µg Ask for price

Recombinant Hepatitis E Virus ORF3 

7-07452 1000µg Ask for price

Hepatitis E Virus ORF3 Recombinant

rAP-5321 Inquiry Ask for price

Anti-Zika Virus Envelope (E) Protein monoclonal Antibody

CABT-B8528 1 mg
EUR 1064.4

Vascular Endothelial Growth Factor-E (Orf Virus), (Recombinant)

22060748-1 2 µg
EUR 146.42

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

7-01759 2µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

7-01760 10µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

7-01761 1mg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

cyt-263-10g 10µg
EUR 145

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

cyt-263-1mg 1mg
EUR 5100

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

cyt-263-2g 2µg
EUR 60

Vascular Endothelial Growth Factor-E Recombinant (Orf Virus)

rAP-2496 Inquiry Ask for price

Human Anti-Hepatitis E Virus Antibody (Anti-HEV) ELISA Kit

abx055821-100g 100 µg Ask for price

Human Anti-Hepatitis E Virus Antibody (Anti-HEV) ELISA Kit

abx055821-200g 200 µg Ask for price

Human Anti-Hepatitis E Virus Antibody (Anti-HEV) ELISA Kit

abx055821-50g 50 µg
EUR 493.75

Hepatitis E virus (ratHEV)

Oneq-V372-OneqV372100R Oneq-V372-100R
EUR 1028

Hepatitis E virus (ratHEV)

Oneq-V372-OneqV372150R Oneq-V372-150R
EUR 1438

Hepatitis E virus (ratHEV)

Oneq-V372-OneqV37250R Oneq-V372-50R
EUR 728

Hepatitis E virus (ratHEV)

PCR-V372-PCRV37248R PCR-V372-48R
EUR 485

Hepatitis E virus (ratHEV)

PCR-V372-PCRV37296R PCR-V372-96R
EUR 685

Hepatitis E Virus protein

30-AH29 1 mg
EUR 895
Description: Hepatitis E Virus recombinant protein

Hepatitis E Virus protein

30R-AH054X 500 ug
EUR 840
Description: Hepatitis E Virus Mosaic recombinant protein

Mouse anti- hepatitis E virus IgM antibody ELISA Kit

ELA-E1791m 96 Tests
EUR 1038

Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892)

MAB12226-100 0.1
EUR 275.56
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893)

MAB12227-100 0.1
EUR 275.56
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894)

MAB12228-100 0.1
EUR 275.56
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132)

MAB12298-100 0.1
EUR 276.84
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132)

MAB12298-500 0.5
EUR 695.29
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133)

MAB12299-100 0.1
EUR 276.84
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133)

Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133)

MAB12299-500 0.5
EUR 695.29
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133)

Anti-Hepatitis B Virus E Antigen Antibody-HRP labled

E38A9930 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody-HRP labled

E38A9937 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody-FITC labled

E38A9941 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody-FITC labled

E38A9948 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Bovine Anti-hepatitis E virus IgG (anti-HEV IgG)ELISA Kit

SL0223Bo - Ask for price

Anti-Hepatitis B Virus E Antigen Antibody-Biotin labled

E38A9952 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody-Biotin labled

E38A9959 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Hepatitis B Virus E Antigen Antibody

20-abx134030
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

Hepatitis B Virus E Antigen Antibody

20-abx134031
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

Hepatitis B Virus e antigen, Antibody

GWB-980E8B 1 mg Ask for price

Hepatitis B Virus E Antigen (HBeAg)

REC31677-100 0.1
EUR 456.72
Description: Recombinant Hepititis B Virus E Protein (HBeAg).

Hepatitis B Virus E Antigen (HBeAg)

REC31677-500 0.5
EUR 1941.06
Description: Recombinant Hepititis B Virus E Protein (HBeAg).

Zika Virus Envelope (ZIKV E) Antibody

abx201401-100l 100 µl
EUR 450

Zika Virus Envelope (ZIKV E) Antibody

abx201401-50l 50 µl
EUR 312.5

Zika Virus Envelope (ZIKV E) Antibody

abx201402-100l 100 µl
EUR 450

Zika Virus Envelope (ZIKV E) Antibody

abx201402-50l 50 µl
EUR 312.5

West Nile Virus E Prot.

GWB-41C2BC 0.1 mg Ask for price

Dengue virus 1 E recombinant antigen

8812 100 ug
EUR 477.6
Description: This is Dengue virus 1 E recombinant antigen for ELISA,WB.

Dengue virus 2 E recombinant antigen

8813 100 ug
EUR 477.6
Description: This is Dengue virus 2 E recombinant antigen for ELISA,WB.

Dengue virus 3 E recombinant antigen

8814 100 ug
EUR 477.6
Description: This is Dengue virus 3 E recombinant antigen for ELISA,WB.

Dengue virus 4 E recombinant antigen

8815 100 ug
EUR 477.6
Description: This is Dengue virus 4 E recombinant antigen for ELISA,WB.

Hepatitis E Virus ORF2 (452-617) Protein

20-abx260268
  • Ask for price
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 100 ug
  • 1 mg

Hepatitis E Virus ORF2 (633-659) Protein

20-abx260269
  • Ask for price
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 100 ug
  • 1 mg

Hepatitis E Virus ORF2 (403-461) Protein

20-abx260270
  • Ask for price
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 100 ug
  • 1 mg

Hepatitis E Virus ORF2 (452-617) Protein

abx260268-20g 20 µg
EUR 950

Hepatitis E Virus ORF2 (452-617) Protein

abx260268-5g 5 µg
EUR 350

Hepatitis E Virus ORF2 (633-659) Protein

abx260269-25g 25 µg
EUR 950

Hepatitis E Virus ORF2 (633-659) Protein

abx260269-5g 5 µg
EUR 350

Hepatitis E Virus ORF2 (403-461) Protein

abx260270-25g 25 µg
EUR 950

Hepatitis E Virus ORF2 (403-461) Protein

abx260270-5g 5 µg
EUR 350

Swine HEPATITIS E virus Antibodies IgM

QY-E40197 96T
EUR 480

Swine HEPATITIS E virus Antibodies IgG

QY-E40198 96T
EUR 480

Hepatitis E virus PCR kit

PCR-H498-48R 50T
EUR 987.6

Hepatitis E virus PCR kit

PCR-H498-96R 100T
EUR 1335.6

Rabbit Anti-Mumps virus (Enders) Virus antiserum

MUMS11-S 0.1 ml
EUR 548.4

Rabbit Anti-Mumps virus (Enders) Virus antiserum

MUMS11-SB 0.5 ml
EUR 1074

Sheep anti-Hepatit E virus IgG(HEV-IgG) Elisa Kit

EK770437 96 Wells
EUR 0.97

Bovine anti-Hepatit E virus IgG(HEV-IgG) Elisa Kit

EK760658 96 Wells
EUR 0.93

Dengue Virus Envelope Protein E Antibody

abx831583-10nmol 10 nmol
EUR 1512.5

Dengue Virus Envelope Protein E Antibody

abx831583-5nmol 5 nmol
EUR 387.5

Human anti-hepatitis B virus e antibody,HBeAb ELISA Kit

201-12-1603 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Respiratory Syncytial Virus (RSV) is the foremost explanation for decrease respiratory tract an infection in infants, in whom, the sensing of RSV by innate immune receptors and its regulation are nonetheless poorly described. Nevertheless, the extreme bronchiolitis following RSV an infection in neonates has been related to a defect in sort I interferons (IFN-I) manufacturing, a cytokine produced primarily by alveolar macrophages (AMs) upon RSV an infection in adults. Within the current research, neonatal C57BL/6 AMs mobilized very weakly the IFN-I pathway upon RSV an infection in vitro and did not restrain virus replication.

Leave a Reply

Your email address will not be published. Required fields are marked *